x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

HCPLive Podcasts

Your destination feed for medical, health care and clinical science podcasts courtesy of HCPLive—featuring our shows Medical Ethics Unpacked, New Insight, and 5 Stories in Under 5.

health & fitness medicine

All Episodes

17:14

How the Newest Dupilumab Approval Solves an "Unmet...

HCPLive Podcasts ·

2022/06/20

Earlier this month, dupilumab became the first and only biologic medicine approved by the US Food and Drug Administration for the treatment of atopic dermatitis in patients of all ages, from infancy through adulthood. The approval of dupilumab as an add-on maintenance therapy for children 6 months to 5 years with moderate to severe atopic dermatitis was described as “a tremendous advancement” by Mercades E. Gonzalez, MD, FAAD, pediatric dermatologist at Pediatric Dermatology of Miami. Gonzalez

en

22:38

Dermatologists Discuss the FDA Approval of...

HCPLive Podcasts ·

2022/06/16

On June 13, the US Food and Drug Administration (FDA) approved oral baricitinib (Olumiant) tablets for the treatment of severe alopecia areata in adults, which marked the first approval of a systemic treatment for the disorder. The approval has excited patients and providers alike who struggled for decades to treat severe cases of this autoimmune disorder. For this episode of DocTalk, several key opinion leaders in the dermatology field sound off on the implications of this decision, as well

en

22:09

Dermatologists Discuss the FDA Approval of...

HCPLive Podcasts ·

2022/06/16

On June 13, the US Food and Drug Administration (FDA) approved oral baricitinib (Olumiant) tablets for the treatment of severe alopecia areata in adults, which marked the first approval of a systemic treatment for the disorder. The approval has excited patients and providers alike who struggled for decades to treat severe cases of this autoimmune disorder. For this episode of DocTalk, several key opinion leaders in the dermatology field sound off on the implications of this decision, as well as

en

21:56

Sleeping Through Infectious Disease and the COVID-19...

HCPLive Podcasts ·

2022/06/14

After presenting at the SLEEP 2022 annual meeting, Dr. Aric Prather explains the findings of his previous research demonstrated lack of sleep (6 hours or less) was associated with a 4 times higher risk of becoming sick after exposure to rhinovirus in an interview with HCPLive. Currently, Prather and his team at UCSF are working with a large naive population for a study that began in March 2021. They've been able to evaluate various aspects of health by following individuals through the COVID-19

en

9:08

Multi-System Approaches to Treating Pediatric Morphea

HCPLive Podcasts ·

2022/06/09

In recognition of National Scleroderma Awareness Month, HCPLive spoke with several prominent dermatologists today who addressed some of the concerns and advancements related to the rare, multi-system disease. Scleroderma is often referred to as “morphea” by dermatologists, and the condition typically presents with the tightening and hardening of the skin. Depending on the region of the body, it can result in everything from swollen joints to lesions on the face, arms, and midsection. For this

en

8:50

Roberto Simons-Linares, MD: The Importance of...

HCPLive Podcasts ·

2022/06/07

en

22:57

Rare Disease Report: Myelodysplastic Syndromes &...

HCPLive Podcasts ·

2022/06/03

Mikkael Sekeres, MD, is no stranger to rare disease. In his own words, there are rare diseases and then there are very rare diseases. Sickle cell is a rare condition with an incidence rate of just over 100 per 100,000 people. Sekeres focuses much of his treatment on patients with bone marrow disorders like myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). These conditions have an incidence rate of approximately 5 per 100,000. In this episode he shares insight on treatment

en

23:57

How Tapinarof Cream 1% is Set to Revolutionize...

HCPLive Podcasts ·

2022/06/01

Last week, the US Food and Drug Administration approved tapinarof cream, 1% (VTAMA) for the treatment of plaque psoriasis of all severities in adult patients, ushering in the first and only FDA-approved steroid-free topical medication in its class. Remarkably, it had been 25 years since a novel chemical entity had been introduced into psoriasis care from a brand-new mechanism of action, and from the data gathered from the phase 3 PSOARING 1 and 2 trials as well as the long term extension (LTE)

en

9:02

Improving Screening Strategies for Cardiac Sarcoidosis

HCPLive Podcasts ·

2022/05/23

In recent years, the acknowledgement of cardiac involvement in patients with sarcoidosis has become increasingly important. Thanks to advanced screening techniques, new research has suggested that approximately 2-5% of patients with sarcoidosis also struggle with cardiac sarcoidosis. However, the practice of adding echocardiography and ambulatory ECG to standard screening with the intention of identifying cardiac sarcoidosis has been deemed controversial by some researchers. Additionally, previous

en

23:15

What's Limiting Medical Marijuana Therapy in...

HCPLive Podcasts ·

2022/05/19

Benjamin Nowell, PhD, and Stuart Silverman, MD, FACP, FACR, discuss the recent publication of a new review article, “Cannabis for rheumatic disease pain: A review of current literature.” Investigators discovered that progress in understanding cannabis-based therapies for treating the pain associated with rheumatic disease is hindered due to a lack of standardization of clinical research and current barriers to conducting such research due to federal and state regulations. Nowell is the Director of

en

16:03

Improving the Availability of COVID-19 Therapeutics...

HCPLive Podcasts ·

2022/05/12

Beyond vaccination, what are some methods for treating COVID-19 in both inpatient and outpatient settings? In the 2 years since the beginning of the pandemic, the strategies for protecting people from this deadly virus have certainly evolved, yet questions remain regarding COVID-19 therapeutics and their availability in certain communities and during times of scarcity. For this episode of DocTalk, Tara Vijayan, MD, MPH, who is a member of the division of infectious diseases at the David Geffen

en

11:45

A Medical Volunteer at the Ukraine-Poland Refugee Border

HCPLive Podcasts ·

2022/05/09

Today's episode features Selena S. Li, MD, a Massachusetts General Hospital surgery resident, who recently traveled overseas with a volunteer medical group to provide treatments and care to refugees escaping the Russian invasion. For more clinical news and expert interviews, visit us at HCPLive.com. To learn more about donating to or volunteering with Medical Volunteers International, click here.

en

11:56

New Methods for Overcoming Environmental and Food...

HCPLive Podcasts ·

2022/05/04

When it comes to allergies, the number of affected individuals in the United States alone is staggering. Approximately 20 million adults and 6 million children in the US are affected by seasonal allergies, and roughly 32 million Americans struggle with a myriad of food allergies. Seasonal allergies have been front-of-mind for many Americans, especially with the Spring season in full effect. The struggles people with seasonal allergies face have no doubt worsened with the introduction of longer and

en

14:20

Evaluating the Efficacy of Faricimab in Patients with...

HCPLive Podcasts ·

2022/05/02

The newly approved ophthalmic drug faricimab (Vabysmo) has already made waves by being the first of its drug class to be approved for both diabetic macular edema (DME) and neovascular age-related degeneration (nAMD). A new phase 4 clinical trial from Genentech seeks to expand on the efficacy of the drug in patients with DME from underrepresented populations. The efficacy and safety of faricimab will be assessed in patients from African American, Hispanic, Latin American, and Indigenous

en

32:01

Rare Disease Report: TANGO2

HCPLive Podcasts ·

2022/04/28

In this hallmark episode, we discuss a condition that has only been documented in 70 cases worldwide. Dr. Amelle Shilligton is a clinical geneticist at Cincinnati Children's Hospital Medical Center. In this conversation, Ashley and Jacob Wiley share the story of how they rushed their 15 month old daughter Aislynn to that hospital, and Dr. Shillington explains how she eventually solved the mystery of Aislynn's diagnosis of TANGO2-related metabolic encephalopathy and arrhythmias. The rare genetic

en

16:52

How Determi-Nation Promotes Diversity in Psoriatic...

HCPLive Podcasts ·

2022/04/28

When addressing psoriatic disease, it is important to consider how it uniquely affects people with skin of color. People from different racial and ethnic groups often struggle with psoriatic disease due to delays in diagnosis, misdiagnosis, and limited access to diagnostic testing and treatment. Furthermore, the lack of access to care and treatment has resulted in biologic use being 69% lower in patients with skin of color compared to white patients. All of these factors stem from a lack of

en

9:03

NAFLD Prevalence Increasing in Pediatric Patients

HCPLive Podcasts ·

2022/04/26

Last week, a new investigation confirmed a higher prevalence of non-alcoholic fatty liver disease (NAFLD) in pediatric patients than previously thought. The data was part of the ongoing observational study called TARGET-NASH, which included participants with NAFLD and/or alcoholic steatohepatitis (NASH). The study, which included 660 pediatric patients, cited an increase in liver disease following evaluation of alanine aminotransferase. Notably, pediatric patients with greater than 250 U/L ATL

en

23:05

Approximately 9 Million More Americans Exposed to Air...

HCPLive Podcasts ·

2022/04/20

Today, the American Lung Association released the 23rd annual “State of the Air” report, which detailed the nationwide exposure to ozone and particle pollution in the United States in 2022. The new report revealed that approximately 9 million more people were affected by particle pollution since last year’s report, with more reported days with “very unhealthy” and “hazardous” air quality than ever published in the 2-decade history of the “State of the Air”. The “State of the Air” report

en

14:20

How JAK Inhibitors Revolutionized Dermatology Care

HCPLive Podcasts ·

2022/04/19

Last summer, Derm Discussions host Brad Glick, DO, invited Brett King, MD, PhD, Yale School of Medicine, to the program to discuss an emerging class of dermatology therapy known as Janus kinase (JAK) inhibitors. At the time, small molecule drugs such as upadacitinib (Rinvoq) were approved for the treatment of conditions like rheumatoid arthritis and ulcerative colitis. Since then, updacacitinib and abrocitinib (Cibinqo) have been approved for use in patients with atopic dermatitis, a skin

en

10:59

Exploring New Possibilities in Vitiligo Therapy

HCPLive Podcasts ·

2022/04/19

An estimated 2 million patients in the United States have vitiligo, which is a dermatologic condition defined by depigmentation of the skin. Though there is currently no cure, recent medical advancements have helped patients and providers alike gain a broader perspective on the skin condition. Likewise, prominent cultural figures with vitiligo have also contributed addressing the stigma surrounding the disease. Despite this, vitiligo is still considered by many to be solely a cosmetic condition,

en

211 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown